FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973721507> ?p ?o ?g. }

• W1973721507 endingPage "173" @default.
• W1973721507 startingPage "168" @default.
• W1973721507 abstract "Background. Cladribine (2-CdA, 2-chlorodeoxyadenosine), a chlorinated adenosine analog, is active in the treatment of hairy cell leukemia and other hematologic malignancies, but its use in treating solid tumors is still under investigation, as is the optimal schedule for administering this drug. The authors conducted a dose-finding study to define the maximal tolerated dose and toxicities of this agent when given to patients with refractory solid tumors having normal renal, hepatic, and bone marrow function. Methods. Cladribine was given as a 1-hour intermittent infusion, repeated daily for 5 days, with a cycle length of 28 days. The initial dose was 4 mg/m2, with escalating doses by cohort. Three dosage levels (4, 6, and 8 mg/m2/day) were explored, and patients were observed to determine toxicity. The end points of the study were the definition of the maximally tolerated dose (MTD), toxicity profile, and establishment of a recommended Phase II dose (RPTD) for cladribine. Results. Eighteen patients were treated; the majority were patients with non-small cell lung cancer and colorectal cancer. The median Cycle-1 leukocyte nadirs for the 4, 6, and 8 mg/m2/day dosage levels were 3100, 2300, and 950 cells/μl (range 800-3500), respectively, and the mean nadir absolute neutrophil counts were 1500, 936, and 482 cells/μl (range 130-2241), respectively. Minimal thrombocytopenia was seen, and no evidence for cumulative myelosuppression was observed. Two patients were hospitalized for neutropenic fevers, both of whom received the 6 mg/m2/day dose. One patient who received the 4 mg/m2/day dose had a transient episode of blindness that occurred during the infusion on Day 3 of Cycle 3. Thorough evaluation of this problem did not reveal an etiology, and it did not recur with further administration of cladribine. No other significant nonhematologic toxicity has been noted. No responses were observed. Conclusions. At the MTD (8 mg/m2/day), the doselimiting toxicity of this agent is myelosuppression. The RPTD for further testing of this schedule is 6 mg/m2 daily × 5 days." @default.
• W1973721507 created "2016-06-24" @default.
• W1973721507 creator A5002019392 @default.
• W1973721507 creator A5005551659 @default.
• W1973721507 creator A5031299191 @default.
• W1973721507 creator A5059219836 @default.
• W1973721507 creator A5063904421 @default.
• W1973721507 creator A5068268371 @default.
• W1973721507 date "1994-07-01" @default.
• W1973721507 modified "2023-10-03" @default.
• W1973721507 title "A phase I study of intermittent infusion cladribine in patients with solid tumors" @default.
• W1973721507 cites W121485390 @default.
• W1973721507 cites W149140897 @default.
• W1973721507 cites W1792577025 @default.
• W1973721507 cites W1876410863 @default.
• W1973721507 cites W1926511128 @default.
• W1973721507 cites W1983066514 @default.
• W1973721507 cites W2074880157 @default.
• W1973721507 cites W2077561098 @default.
• W1973721507 cites W2096748176 @default.
• W1973721507 cites W2226762558 @default.
• W1973721507 cites W2314659489 @default.
• W1973721507 cites W2317201497 @default.
• W1973721507 cites W2328002422 @default.
• W1973721507 cites W2343494993 @default.
• W1973721507 cites W4232231972 @default.
• W1973721507 cites W4233161682 @default.
• W1973721507 cites W4239548556 @default.
• W1973721507 doi "https://doi.org/10.1002/1097-0142(19940701)74:1<168::aid-cncr2820740127>3.0.co;2-t" @default.
• W1973721507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7911736" @default.
• W1973721507 hasPublicationYear "1994" @default.
• W1973721507 type Work @default.
• W1973721507 sameAs 1973721507 @default.
• W1973721507 citedByCount "14" @default.
• W1973721507 countsByYear W19737215072019 @default.
• W1973721507 countsByYear W19737215072023 @default.
• W1973721507 crossrefType "journal-article" @default.
• W1973721507 hasAuthorship W1973721507A5002019392 @default.
• W1973721507 hasAuthorship W1973721507A5005551659 @default.
• W1973721507 hasAuthorship W1973721507A5031299191 @default.
• W1973721507 hasAuthorship W1973721507A5059219836 @default.
• W1973721507 hasAuthorship W1973721507A5063904421 @default.
• W1973721507 hasAuthorship W1973721507A5068268371 @default.
• W1973721507 hasBestOaLocation W19737215071 @default.
• W1973721507 hasConcept C121332964 @default.
• W1973721507 hasConcept C126322002 @default.
• W1973721507 hasConcept C141071460 @default.
• W1973721507 hasConcept C142424586 @default.
• W1973721507 hasConcept C151032500 @default.
• W1973721507 hasConcept C2776694085 @default.
• W1973721507 hasConcept C2777063308 @default.
• W1973721507 hasConcept C2779200787 @default.
• W1973721507 hasConcept C2780873365 @default.
• W1973721507 hasConcept C29730261 @default.
• W1973721507 hasConcept C71924100 @default.
• W1973721507 hasConcept C74133956 @default.
• W1973721507 hasConcept C87355193 @default.
• W1973721507 hasConcept C90924648 @default.
• W1973721507 hasConceptScore W1973721507C121332964 @default.
• W1973721507 hasConceptScore W1973721507C126322002 @default.
• W1973721507 hasConceptScore W1973721507C141071460 @default.
• W1973721507 hasConceptScore W1973721507C142424586 @default.
• W1973721507 hasConceptScore W1973721507C151032500 @default.
• W1973721507 hasConceptScore W1973721507C2776694085 @default.
• W1973721507 hasConceptScore W1973721507C2777063308 @default.
• W1973721507 hasConceptScore W1973721507C2779200787 @default.
• W1973721507 hasConceptScore W1973721507C2780873365 @default.
• W1973721507 hasConceptScore W1973721507C29730261 @default.
• W1973721507 hasConceptScore W1973721507C71924100 @default.
• W1973721507 hasConceptScore W1973721507C74133956 @default.
• W1973721507 hasConceptScore W1973721507C87355193 @default.
• W1973721507 hasConceptScore W1973721507C90924648 @default.
• W1973721507 hasIssue "1" @default.
• W1973721507 hasLocation W19737215071 @default.
• W1973721507 hasLocation W19737215072 @default.
• W1973721507 hasOpenAccess W1973721507 @default.
• W1973721507 hasPrimaryLocation W19737215071 @default.
• W1973721507 hasRelatedWork W1913757185 @default.
• W1973721507 hasRelatedWork W1999706042 @default.
• W1973721507 hasRelatedWork W2058955695 @default.
• W1973721507 hasRelatedWork W2114989931 @default.
• W1973721507 hasRelatedWork W2364106504 @default.
• W1973721507 hasRelatedWork W2374626322 @default.
• W1973721507 hasRelatedWork W2385675040 @default.
• W1973721507 hasRelatedWork W2399260915 @default.
• W1973721507 hasRelatedWork W4224865302 @default.
• W1973721507 hasRelatedWork W4236385432 @default.
• W1973721507 hasVolume "74" @default.
• W1973721507 isParatext "false" @default.
• W1973721507 isRetracted "false" @default.
• W1973721507 magId "1973721507" @default.
• W1973721507 workType "article" @default.